Even though in these cell culture models defective MMR is considered a minor contributor for the cisplatin resistance phenotype [74,75], the preclinical observations still imply that the loss of MMR function might have an adverse effect on cisplatin efficacy in cancer therapy. Here, MRC1 is linked to cancer.